Orally-disintegrating porous tablets with microscopic pores comprising an effective amount of glycopyrrolate with the disintegration rate in the mouth of less than 60 seconds and an increased bioavailability. Methods for treating sialorrhea, controlling excessive production of stomach acid, controlling excessive sweating, managing stomach and/or abdominal pain, and treating drug-induced arrhythmia.

The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.

A pharmaceutical composition comprising tricalcium phosphate and gelatin for use in a method for the treatment of dyspepsia, acidic mouth and and/or canker sores is disclosed.

The present invention relates to compounds useful in the prophylaxis and/or treatment of one or more fibrotic diseases. In particular, the compounds of the invention antagonize GPR84, a G-protein-coupled receptor. The present invention also provides pharmaceutical compositions comprising the compounds for use and methods for the prophylaxis and/or treatment of one or more fibrotic diseases by administering said compound.

Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

The invention relates to pharmaceutical compositions for direct systemic introduction, are also known as DSI pharmaceutical compositions, for used as human veterinary pharmaceutical compositions. In one embodiment, the invention relates to a pharmaceutical composition for direct system introduction comprising bovine gelatin, mannitol, an optional surfactant, an optional flavorant, and an active pharmaceutical ingredient. A DSI pharmaceutical composition of the invention has a disintegration time of 7 seconds or less in deionized water maintained at 37.0 C.0.5 C. The invention also relates to a method of delivering an active pharmaceutical ingredient to an animal comprising the step of placing a DSI pharmaceutical composition of the invention into a mucosal cavity of an animal to be treated with the active pharmaceutical ingredient and to the corresponding methods of treatment.

Compounds are provided according to Formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, Y, R.sup.1, R.sup.2a, R.sup.2b, R.sup.4a, R.sup.4b, R.sup.5a, R.sup.5b, R.sup.6a, R.sup.6b, R.sup.7, and R.sup.8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

The purpose of present invention to provide a method for the production of an easy-to-take solid preparation, which is mainly characterized in that an outer layer-forming processing to provide an easy-to-take property is simply performed in a dry process without going through a wet condition so as to make the formed outer layer thicker; the easy-to-take solid preparation and the like. The present invention relates to a dry-process method for the production of an easy-to-take solid preparation wherein an inner core tablet is coated with a compression-molded outer layer-forming agent comprising a gelling agent that will show slipperiness when it is brought into contact with water, comprising loading separately or simultaneously the inner core tablet and powder of the outer layer-forming agent to a mortar inner surface, the bottom end surface of an upper-pestle, and the top end surface of a lower-pestle, and subsequently compression-molding them; a powder composition for coating a solid preparation for use in the above method, which comprises the water-soluble polymer and water-soluble sugar or sugar alcohol.

An effervescent powder product containing cannabinoids, terpenes and cannabidiol (CBD) and a process for producing an effervescent supplement powder. The effervescent powder having a density that enables the effervescent powder to break apart and/or dissolve when it is added to or submerged in any liquid, including non-carbonated and carbonated liquids, with or without stirring. The floating delivery system yields an effervescent powder bulk density that is lower than the gastric fluid and allows the active components to remain buoyant for extended time periods without affecting the rate of gastric emptying.

In an example implementation, a method of producing an ingredient delivery device includes applying a layer of powder within a work space, selectively depositing a liquid active ingredient onto the powder layer where the liquid active ingredient is to function as a fusing agent, and applying fusing energy to the powder layer to control a release profile of the active ingredient upon ingestion of the ingredient delivery device by a user.